Neurocrine Biosciences, Inc (NASDAQ:NBIX) shares, rose in value on Friday, July 11, with the stock price down by -1.08% to the previous day’s close as strong demand from buyers drove the stock to $133.46.
Actively observing the price movement in the last trading, the stock closed the session at $134.92, falling within a range of $132.1 and $135.0025. The value of beta (5-year monthly) was 0.241 whereas the PE ratio was 45.25 over 12-month period. Referring to stock’s 52-week performance, its high was $157.98, and the low was $84.23. On the whole, NBIX has fluctuated by 6.96% over the past month.
With the market capitalization of Neurocrine Biosciences, Inc currently standing at about $13.21 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-05.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 2.69B, with a low estimate of 612M and a high estimate of 682.7M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 653.09M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NBIX’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 1.32, with the price of NBIX currently trading nearly 4.36% and 8.34% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 67.75, while the 7-day volatility ratio is showing 2.30% which for the 30-day chart, stands at 2.19%. Furthermore, Neurocrine Biosciences, Inc (NBIX)’s beta value is 0.25.
A comparison of Neurocrine Biosciences, Inc (NBIX) with its peers suggests the former has fared considerably weaker in the market. NBIX showed an intraday change of -1.08% in last session, and over the past year, it shrunk by -2.23%%.
Data on historical trading for Neurocrine Biosciences, Inc (NASDAQ:NBIX) indicates that the trading volumes over the past 10 days have averaged 0.88 and over the past 3 months, they’ve averaged 1.28 million. According to company’s latest data on outstanding shares, there are 99.00 million shares outstanding.
Nearly 3.54% of Neurocrine Biosciences, Inc’s shares belong to company insiders and institutional investors own 94.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.5 million shares as on 2025-06-13, resulting in a short ratio of 3.39. According to the data, the short interest in Neurocrine Biosciences, Inc (NBIX) stood at 472.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 4.03 million. The stock has fallen by -6.87% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NBIX stock heading into the next quarter.
